within Pharmacolibrary.Drugs.ATC.G;

model G01AF21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 5.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0003,
    Tlag           = 0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G01AF21</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tinidazole is a synthetic 5-nitroimidazole antimicrobial agent primarily used for the treatment of protozoal infections such as giardiasis, amoebiasis, and trichomoniasis, and for certain anaerobic bacterial infections. It is a well-absorbed oral medication and remains approved in many countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Mergenhagen, KA, et al., &amp; Russo, TA (2020). Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. <i>Antimicrobial agents and chemotherapy</i> 64(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02167-19\">10.1128/AAC.02167-19</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31871085/\">https://pubmed.ncbi.nlm.nih.gov/31871085</a></p></li><li><p>Lamp, KC, et al., &amp; Lacy, MK (1999). Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clinical pharmacokinetics</i> 36(5) 353–373. DOI:<a href=\"https://doi.org/10.2165/00003088-199936050-00004\">10.2165/00003088-199936050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10384859/\">https://pubmed.ncbi.nlm.nih.gov/10384859</a></p></li><li><p>Wood, BA, &amp; Monro, AM (1975). Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. <i>The British journal of venereal diseases</i> 51(1) 51–53. DOI:<a href=\"https://doi.org/10.1136/sti.51.1.51\">10.1136/sti.51.1.51</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1092424/\">https://pubmed.ncbi.nlm.nih.gov/1092424</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G01AF21;
